MARKET

AARD

AARD

Aardvark Therapeutics
NASDAQ
12.40
+0.47
+3.94%
After Hours: 12.40 0 0.00% 18:55 12/04 EST
OPEN
12.00
PREV CLOSE
11.93
HIGH
12.83
LOW
11.90
VOLUME
241.92K
TURNOVER
--
52 WEEK HIGH
19.58
52 WEEK LOW
4.880
MARKET CAP
269.99M
P/E (TTM)
-4.9014
1D
5D
1M
3M
1Y
5Y
1D
Individual investors among Aardvark Therapeutics, Inc.'s (NASDAQ:AARD) largest shareholders, saw gain in holdings value after stock jumped 23% last week
Simply Wall St · 20h ago
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Closing Bell Movers: Marvell up 11%, reversing initial earnings selloff
TipRanks · 2d ago
Aardvark Therapeutics, Inc. (AARD) Gets a Buy from Raymond James
TipRanks · 2d ago
Aardvark Therapeutics initiated with a Strong Buy at Raymond James
TipRanks · 2d ago
Weekly Report: what happened at AARD last week (1124-1128)?
Weekly Report · 3d ago
Weekly Report: what happened at AARD last week (1117-1121)?
Weekly Report · 11/24 10:40
Catalyst Watch: Alibaba earnings, AI anxiety, airline M&A, and a Burry teaser
Seeking Alpha · 11/21 20:00
More
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).

Webull offers Aardvark Therapeutics, Inc. stock information, including NASDAQ: AARD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AARD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AARD stock methods without spending real money on the virtual paper trading platform.